Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Device aims to build dialysis access from inside the blood vessels

NCT ID NCT07034092

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

People with end-stage kidney disease need a reliable blood vessel connection, called a fistula, for hemodialysis. This study tests a device called the ePATH System, which creates that connection from inside the blood vessels rather than through open surgery. Researchers will follow about 20 adults who need or will soon need dialysis to see whether the procedure is safe and whether the fistula works in the first few months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
The ePATH System, a device that creates a fistula between an artery and a vein from inside the blood vessels
What this could lead to
If it works, this could offer a less invasive way to create the vascular access people with kidney failure need for dialysis.
What could go wrong
This is a small feasibility study, so it can only show whether the approach is safe enough and works technically in a few patients. The fistula may fail to stay open, or the device could cause complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2027

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients deemed eligible for creation of an AV fistula according to institutional or local guidelines and/or clinical judgement of the investigator 2. Adults (age \>18 years old) 3. Non-reversible kidney failure requiring hemodialysis (this can include pre-dialysis patients) 4. Target vein diameter of ≥2.0 mm 5. Target artery diameter of ≥2.0 mm 6. Both radial and ulnar artery flow to the hand, confirmed with Duplex Ultrasound and/or Allen's test (i.e. palmar arch) 7. Able to provide informed consent 8. Able to comply with follow-up visit assessment requirements 9. Patient is free from clinically significant conditions or illnesses that might compromise the procedure or the AVF Exclusion Criteria: 1. Significant central venous stenosis or narrowing that exceeds 50% based on imaging 2. Hypercoagulable state or known bleeding diathesis 3. NHYA Class III or IV heart failure 4. Estimated life-expectancy of \<1 year based on the physician's opinion 5. Oedema of extremities 6. Current diagnosis of carcinoma 7. Pregnant or breastfeeding women 8. Diagnosed or suspected skin disease at the access site 9. Immunosuppression or otherwise immunocompromised patients 10. Currently being treated with another investigational device or medication 11. Allergy to contrast or other drugs associated with surgery, e.g., sedation agents, or to device materials 12. Anatomy that prevents formation of AVF, e.g., misalignment of vessels or tortuosity 13. Patient is unwilling to undergo 2nd stage procedure, e.g. endovascular prothesis placement or balloon dilatation, if required

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney disease, end-stage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sanatorio Italiano

    Asunción, 001207, Paraguay

More trials for these conditions

Other studies related to the condition(s) this trial covers.